Andre Larente - Diagnos CEO and President and Executive Director
| ADK Stock | CAD 0.28 0.01 3.70% |
CEO
Mr. Andre Larente is the President, Director of Diagnos Inc since 2000.
| Tenure | 24 years |
| Address | 7005 Taschereau Boulevard, Brossard, QC, Canada, J4Z 1A7 |
| Phone | 450 678 8882 |
| Web | https://www.diagnos.ca |
Diagnos Management Efficiency
The company has return on total asset (ROA) of (1.3433) % which means that it has lost $1.3433 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (24.5157) %, meaning that it generated substantial loss on money invested by shareholders. Diagnos' management efficiency ratios could be used to measure how well Diagnos manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to climb to -4.47 in 2024. Return On Capital Employed is likely to drop to 2.66 in 2024. At this time, Diagnos' Non Currrent Assets Other are fairly stable compared to the past year. Other Current Assets is likely to climb to about 27.6 K in 2024, whereas Non Current Assets Total are likely to drop slightly above 256.8 K in 2024.Similar Executives
| Found 2 records | CEO Age | ||
| Hugh MacNaught | VentriPoint Diagnostics | N/A | |
| Roger DumoulinWhite | Theralase Technologies | N/A | |
Management Performance
| Return On Equity | -24.52 | ||||
| Return On Asset | -1.34 |
Diagnos Leadership Team
Elected by the shareholders, the Diagnos' board of directors comprises two types of representatives: Diagnos inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Diagnos. The board's role is to monitor Diagnos' management team and ensure that shareholders' interests are well served. Diagnos' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Diagnos' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Martin Beland, Director Marketing | ||
| YvesStphane Couture, Chief Officer | ||
| Guillermo Robles, Vice President - Health Care Business Development of Latin America | ||
| MarcAndr Massue, CFO Finance | ||
| Andre Larente, CEO and President and Executive Director |
Diagnos Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Diagnos a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -24.52 | ||||
| Return On Asset | -1.34 | ||||
| Operating Margin | (15.76) % | ||||
| Current Valuation | 29.65 M | ||||
| Shares Outstanding | 95 M | ||||
| Shares Owned By Insiders | 14.41 % | ||||
| Shares Owned By Institutions | 0.01 % | ||||
| Number Of Shares Shorted | 66.56 K | ||||
| Price To Earning | (2.76) X | ||||
| Price To Book | 54.61 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Diagnos Stock Analysis
When running Diagnos' price analysis, check to measure Diagnos' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Diagnos is operating at the current time. Most of Diagnos' value examination focuses on studying past and present price action to predict the probability of Diagnos' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Diagnos' price. Additionally, you may evaluate how the addition of Diagnos to your portfolios can decrease your overall portfolio volatility.